Syngene International Limited – Investor Presentation Summary

Key Operational Highlights

  • Integrated Drug Discovery (IDD) offerings were strengthened by bringing Chemistry, Biology and Biotherapeutics under the unified leadership of Chief Scientific Officer Dr. Jayashree Aiyar.
  • Signed first manufacturing agreement for the Bayview biologics facility with a large pharmaceutical customer, with process development scheduled to begin in India in 2026 followed by drug-substance manufacturing at Bayview in 2027.
  • Secured additional biologics manufacturing contracts, including an agreement to supply clinical materials from its Bengaluru biologics facility (Unit 3).
  • Commissioned a Clinical Translational Sciences laboratory in Bengaluru, integrating clinical biomarker development and validation, biobanking, patient stratification, precision medicine and bioanalytical capabilities.
  • Expanded digital capabilities through ChemVoyager, automated analytical systems and end-to-end sample tracking.
  • Continued implementing cost-optimization initiatives to improve operational efficiency, with manpower-related optimization completed.
  • Total headcount stands at 8,373 employees, including 5,778 scientists (7% PhDs).

Key drivers of operational performance: New facility agreements, capability enhancements in translational sciences and digital tools, and cost optimization initiatives.

Financial Highlights

Q2 FY27 Performance:

  • Revenue from Operations: ₹833 Cr (+13% Q-o-Q, -9% Y-o-Y)
  • Operating EBITDA Margin: 18% (12% in Q1FY27, 22% in Q2FY26)
  • PAT before exceptional items: ₹38 Cr (₹1 Cr in Q1FY27, ₹67 Cr in Q2FY26)
  • PAT after exceptional items: ₹32 Cr (₹9 Cr loss in Q1FY27, ₹67 Cr in Q2FY26)
  • Exceptional expenses: ₹6 Cr (net of tax) for employee termination benefits in Q2 FY27

H1 FY27 Performance:

  • Revenue from Operations: ₹1,569 Cr (-12% Y-o-Y)
  • Operating EBITDA Margin: 15% (23% in H1FY26)
  • PAT before exceptional items: ₹39 Cr (₹154 Cr in H1FY26)
  • PAT after exceptional items: ₹23 Cr (₹154 Cr in H1FY26)
  • Exceptional expenses: ₹16 Cr (net of tax) for employee termination benefits in H1 FY27

FY26 Annual Performance:

  • Revenue from Operations: ₹3,739 Cr (+3% Y-o-Y)
  • Operating EBITDA Margin: 25% (29% in FY25)
  • PAT before exceptional items: ₹380 Cr (-20% Y-o-Y)
  • PAT Margin: 10.0% (12.8% in FY25)

Drivers of financial performance: Lower revenues and foreign exchange hedge losses impacted margins. Adjusted for forex hedge loss, the operating EBITDA margin for Q2 FY27 would be in the mid-20s range.

Balance Sheet Snapshot

As of September 30, 2026:

  • Shareholders' funds: ₹4,859 Cr
  • Net Fixed Assets: ₹4,021 Cr
  • Other Net Assets: -₹554 Cr
  • Net Cash: ₹1,392 Cr

As of March 31, 2026:

  • Shareholders' funds: ₹4,839 Cr
  • Net Fixed Assets: ₹4,046 Cr
  • Other Net Assets: -₹1,007 Cr
  • Net Cash: ₹1,800 Cr

Financial Health Insights: Strong cash position with net cash of ₹1,392 Cr as of September 30, 2026.

Capex & Cash Flow Health

Not Specified

Strategic & R&D Initiatives

  • Implementing a comprehensive strategy for biologics development and manufacturing, establishing seamless one-stop-shop capability from discovery to commercial production.
  • Utilizing existing CMC capabilities and commercial manufacturing while developing innovative technologies for small molecule services.
  • Driving operational excellence through improved reliability, speed and efficiency.
  • Building future-ready organization through leadership development and employee well-being initiatives.
  • Investments in emerging modalities such as peptides and ADCs to align with global demand.

Industry Trends & Business Environment

Not Specified

Management Commentary & Growth Outlook

Not Specified

ESG Updates

  • 92% energy from renewable sources
  • 61% reduction of SBTi Scope 1 & 2 emissions, exceeding target of 54.6%
  • 95% of energy procured from renewable energy sources
  • 73,741 tCO2e of GHG emissions avoided
  • 97% of total hazardous and non-hazardous waste recycled
  • Zero waste to direct landfill
  • 58% YoY freshwater savings achieved
  • 1,14,633 KL fresh water saved from recycling, reusing and rainwater harvesting
  • Recognized by TIME Magazine and Statista as World's Most Sustainable Companies 2025 and 2026
  • EcoVadis 2025 score improved to 74/100, placing Syngene in the 91st percentile globally

Awards and Recognition

  • CDMO Leadership Award 2025: Winner in Biologics category
  • Biopharma Excellence Awards 2025 (India Edition): Best Bioprocessing Supplier Analytical Services
  • Pharma Supply Chain Champion 2025: Ranked #1 among mid-sized pharma and API firms
  • TIME Magazine & Statista – World's Most Sustainable Companies 2026: Ranked among global top three and #1 in India in Pharma & Biotech
  • S&P Global Sustainability Yearbook 2026: Ranked among top 10 life sciences companies and top 9% globally
  • NAMC Gold Award: Biologics Manufacturing Excellence
  • Achieved My Green Lab 'Green Certification' (>94% score) for laboratories